The roles of Y-box-binding protein (YB)-1 and C-X-C motif chemokine ligand 14 (CXCL14) in the progression of prostate cancer via extracellular-signal-regulated kinase (ERK) signaling

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010;17(4):R305–315.
   PubMed Web of Science ®Google Scholar
• Kohno K, Izumi H, Uchiumi T, et al. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25(7):691–698.
   PubMed Web of Science ®Google Scholar
• Guo T, Yu Y, Yip GW, et al. Y-box binding protein 1 is correlated with lymph node metastasis in intestinal-type gastric cancer. Histopathology. 2015;66(4):491–499.
   PubMed Web of Science ®Google Scholar
• Bhullar J, Sollars VE. YBX1 expression and function in early hematopoiesis and leukemic cells. Immunogenetics. 2011;63(6):337–350.
   PubMed Web of Science ®Google Scholar
• Kashihara M, Azuma K, Kawahara A, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 2009;4(9):1066–1074.
   PubMed Web of Science ®Google Scholar
• Fujiwara-Okada Y, Matsumoto Y, Fukushi J, et al. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer. 2013;108(4):836–847.
   PubMed Web of Science ®Google Scholar
• Kolk A, Jubitz N, Mengele K, et al. Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients. Br J Cancer. 2011;105(12):1864–1873.
   PubMed Web of Science ®Google Scholar
• Giménez-Bonafé P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59(3):337–349.
   PubMed Web of Science ®Google Scholar
• Liu TT, Arango-Argoty G, Li Z, et al. Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells. Rna. 2015;21(6):1159–1172.
   PubMed Web of Science ®Google Scholar
• De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008;214(3):559–567.
   PubMed Web of Science ®Google Scholar
• Chang YS, Chen WY, Yin JJ, et al. EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 2015;75(15):3077–3086.
   PubMed Web of Science ®Google Scholar
• Kurth I, Willimann K, Schaerli P, et al. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001;194(6):855–861.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Kato Y, Ito S, et al. Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci. 2009;100(11):2202–2209.
   PubMed Web of Science ®Google Scholar
• Nakayama R, Arikawa K, Bhawal UK, Nakayama R, Arikawa K, Bhawal UK. The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancers. J Cancer. 2017;8(15):3014–3027.
   PubMed Web of Science ®Google Scholar
• Berquin IM, Pang B, Dziubinski ML, et al. Y-box-binding protein 1 confers EGF Independence to human mammary epithelial cells. Oncogene. 2005;24(19):3177–3186.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Ruzanov P, Anglesio MS, et al. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol. 2006;26(1):277–292.
   PubMed Web of Science ®Google Scholar
• Bader AG, Felts KA, Jiang N, et al. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A. 2003;100(21):12384–12389.
   PubMed Web of Science ®Google Scholar
• Coles LS, Lambrusco L, Burrows J, et al. Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett. 2005;579(24):5372–5378.
   PubMed Web of Science ®Google Scholar
• Jürchott K, Kuban RJ, Krech T, et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010;6(12):e1001231.
   PubMed Web of Science ®Google Scholar
• Ma R, Li X, Tewari N, et al. microRNA-21 ameliorates the impairment of autophagy in palatal wound healing. J Physiol Pharmacol. 2020;71:6.
   Web of Science ®Google Scholar
• Szczuraszek K, Halon A, Materna V, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin’s lymphomas. Anticancer Res. 2011;31(9):2963–2970.
   PubMed Web of Science ®Google Scholar
• Maciejczyk A, Szelachowska J, Ekiert M, et al. Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res. 2012;32(8):3177–3184.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yamada S, Izumi H, et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol. 2012;105(7):724–730.
   PubMed Web of Science ®Google Scholar
• Wu J, Lee C, Yokom D, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66(9):4872–4879.
   PubMed Web of Science ®Google Scholar
• Em D, Hunzicker-Dunn ME. Extracellular signal-regulated Kinase (ERK)-dependent phosphorylation of Y-Box-binding protein 1 (YB-1) enhances gene expression in granulosa cells in response to Follicle-stimulating Hormone (FSH). J Biol Chem. 2016;291(23):12145–12160.
   PubMed Web of Science ®Google Scholar
• Nishio S, Ushijima K, Yamaguchi T, et al. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer. Gynecol Oncol. 2014;132(3):703–708.
   PubMed Web of Science ®Google Scholar
• Panupinthu N, Yu S, Zhang D, et al. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 2014;33(22):2846–2856.
   PubMed Web of Science ®Google Scholar
• Feng Q, Huang S, Zhang A, et al. Y-box protein 1 stimulates mesangial cell proliferation via activation of ERK1/2. Nephron Exp Nephrol. 2009;113(1):e16–25.
   PubMedGoogle Scholar
• Hu S, Duan YX, Zhou Q, et al. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis. IUBMB Life. 2019;71(7):928–941.
   Google Scholar
• Sutherland BW, Kucab J, Wu J, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24(26):4281–4292.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15(5):402–415.
   PubMed Web of Science ®Google Scholar
• Hata R, Izukuri K, Kato Y, et al. Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice. Sci Rep. 2015;5(1):9083.
   PubMedGoogle Scholar
• Hara T, Tanegashima K. Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. J Biochem. 2012;151(5):469–476.
   PubMed Web of Science ®Google Scholar
• Sand LG, Scotlandi K, Berghuis D, et al. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients. Eur J Cancer. 2015;51(17):2624–2633.
   PubMed Web of Science ®Google Scholar
• Sjöberg E, Augsten M, Bergh J, et al. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. Br J Cancer. 2016;114(10):1117–1124.
   PubMed Web of Science ®Google Scholar
• Chiu SH, Chen CC, Lin TH. Using support vector regression to model the correlation between the clinical metastases time and gene expression profile for breast cancer. Artif Intell Med. 2008;44(3):221–231.
   PubMed Web of Science ®Google Scholar
• Zeng J, Yang X, Cheng L, et al. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med. 2013;11(1):6.
   PubMedGoogle Scholar
• Miyoshi H, Ajima R, Luo CT, et al. Wnt5a potentiates TGF-β signaling to promote colonic crypt regeneration after tissue injury. Science. 2012;338(6103):108–113.
   PubMed Web of Science ®Google Scholar
• Lin K, Zou R, Lin F, et al. Expression and effect of CXCL14 in colorectal carcinoma. Mol Med Rep. 2014;10(3):1561–1568.
   PubMed Web of Science ®Google Scholar